Latest News and Press Releases
Want to stay updated on the latest news?
- 
                            
RENO, Nev., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today...
 - 
                            
Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel...
 - 
                            
Trading of Phoenix Energy's Preferred Stock is Expected to Start This Morning, September 30, 2025, on NYSE American Under the Symbol “PHXE.P."
 - 
                            
Trading of Phoenix Energy's Preferred Stock Expected to Begin September 30, 2025 on NYSE American Under the Symbol “PHXE.P.”
 - 
                            
GUANGZHOU, CHINA, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Youxin Technology Ltd (NASDAQ: YAAS) (the “Company”), a software as a service (“SaaS”) and platform as a service (“PaaS”) provider committed to...
 - 
                            
Propanc Biopharma closes an underwritten public offering of 1,000,000 shares of its common stock at a price of $4.00 per share
 - 
                            
Los Angeles, CA, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), a gold...
 - 
                            
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”), which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM), today...
 - 
                            
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (“BioSig” or the “Company”) which recently merged with Streamex Exchange Corporation (“Streamex”) (NASDAQ: BSGM) today...
 - 
                            
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...